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To investigate the diﬀerent eﬀects between sulfonylurea (SU) and glinide drugs in insulin secretion, pancreatic β-cells were
repeatedly stimulated with SU (glimepiride) or glinide (mitiglinide). Total internal reﬂection ﬂuorescent (TIRF) microscopy
revealed that secondary stimulation with glimepiride, but not glucose and mitiglinide, failed to evoke fusions of insulin granules
although primary stimulation with glucose, glimepiride, and mitiglinide induced equivalent numbers of exocytotic responses.
Glimepiride, but not glucose and mitiglinide, induced abnormally sustained [Ca
2+]i elevations and reductions of docked insulin
granules on the plasma membrane. Our data suggest that the eﬀect of glinide on insulin secretory mechanisms is similar to that of
glucose.
Copyright © 2009 Kyota Aoyagi et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Sulfonylurea (SU) and glinide drugs are commonly used
for the treatment of type 2 diabetic patients to stimulate
insulin release from pancreatic β-cells. Both insulinotropic
reagents have distinct structures but bind to the same target,
SURs, a subunit of the ATP-sensitive K+ channel, resulting
in the channel closure, which induces depolarization and
subsequent Ca2+ inﬂux through voltage-gated Ca2+ channel,
followed by Ca2+-dependent exocytosis of insulin granules
[1].
Despite their similar insulinotropic eﬀects, we found
striking diﬀerences in the restoration of β-cell function in
diabetic GK rats [2]. GK rats show abnormal pancreatic islet
morphology, and the glucose-induced exocytotic response
and the numbers of docked insulin granules on the plasma
membrane are impaired in pancreatic β-cells cultured
from GK rats. We found that long-term treatment with
nateglinide, a glinide drug, caused partial recovery of these
impairments in GK rats; the glucose-induced exocytotic
response in β-cells cultured from GK rats treated with
nateglinide for 6 weeks was partially recovered. In addition,
the glinide-treatment almost restored the pancreatic islet
morphology and the number of docked insulin granules
on the plasma membrane. On the other hand, long-term
treatment with glibenclamide, an SU drug, did not restore
the β-cell functions in GK rats.
One of the explanations for their diﬀerent eﬀects on the
recovery of β-cell function would be the diﬀerent potency
of SU and glinides. While SUs bind tightly to SURs and
exhibit a delayed onset and prolonged hypoglycemic eﬀects,
glinides have a rapid onset and short acting eﬀects on insulin
secretion[3].BecauseseveralreportsshowedthatchronicSU
treatment induced unresponsiveness of β-cells to SU drugs
i nv i v oa n di nv i t r o[ 4, 5], it has been suggested that SU
stimulation could cause an impairment of insulin-secretory
mechanism in β-cells.
To examine the eﬀects of these drugs on the exocy-
totic response in β-cells, we studied the reversibility of
insulin-secreting responses to repetitive glucose, SU, or2 Experimental Diabetes Research
glinide stimulations in primary cultured mouse pancreatic
β-cells.
2.MaterialsandMethods
2.1. Total Internal Reﬂection Fluorescent (TIRF) Microscopy
Analysis. Pancreatic β-cells were cultured from C57BL/6
mice, infected with recombinant adenovirus to express GFP-
tagged insulin and observed under the Olympus TIRF
microscope with a high-aperture objective lens as described
previously [2]. Cultured β-cells were incubated for 15
minutes at 37
◦C in Krebs-Ringer buﬀer (KRB) containing
(in mM): 110 NaCl, 4.4 KCl, 1.45 KH2PO4,1 . 2M g S O 4,
2.3 calcium gluconate, 4.8 NaHCO3, 4 glucose, 10 HEPES,
pH 7.4, and 0.3% bovine serum albumin (BSA). Cells were
then perifused with KRB with 4mM glucose at a ﬂow
rate of 0.5mL/min and stimulated with KRB containing
16.7mMglucose,5.5mMglucosesupplementedwith0.5μM
mitiglinide or glimepiride for 12.5 minutes. After the ﬁrst
stimulation, KRB buﬀer containing 4mM glucose was
perifused for 15 minutes, followed by the second stimulation
with 16.7mM glucose, 5.5mM glucose supplemented with
0.5μM mitiglinide or glimepiride for 12.5 minutes. The
numbers of fusion events during the ﬁrst and second stimuli
and the numbers of docked insulin granules just before the
ﬁrst and second stimulations were manually counted.
2.2. Measurement of [Ca2+]i. Fura-2 acetoxymethyl ester
(Fura-2 AM; Invitrogen) was loaded into cultured β-cells
and the ARGUS/HiSCA system (Hamamatsu photonics) was
used for [Ca2+]i measurement as previously described [2].
Cells were repeatedly stimulated as described above.
2.3. Statistical Analyses. Data were analysed by one-way
ANOVA followed by Turky-Kramer’s test using the Statview
software (SAS Institute, Cary, NC, U.S.A.).
3. Results
First, we performed repetitive stimulations using physio-
logical stimulation, high glucose. Primary cultured mouse
pancreatic β-cells expressing GFP-tagged insulin were stim-
ulated twice by perifusion with 16.7mM glucose, and the
exocytotic responses to the ﬁrst and second stimulations
were observed under TIRF microscopy. Figure 1(a) shows
the numbers of exocytotic events from pre-docked and
newcomer granules in response to the ﬁrst and second high
glucose stimuli. The patterns of exocytotic events during the
ﬁrst and second stimulations were similar indicating that
16.7mM glucose could repeatedly evoke qualitatively similar
exocytotic responses.
Next, we examined whether the repetitive exocytotic
response could be induced by commonly used insulinotropic
reagents, SU, and glinide drugs. Glimepiride and mitiglinide
were used as representative SU and glinide drugs, respec-
tively. As shown in Figure 1(b), both the ﬁrst and second
mitiglinide stimulations quickly elicited exocytotic responses
after the onset of stimulation, although the number of
total fusion events evoked by the second mitiglinide stim-
ulus was mildly reduced. On the other hand, glimepiride,
surprisingly, failed to evoke the exocytotic response dur-
ing second stimulus (Figure 1(c)). The number of total
fusion events induced by the ﬁrst glimepiride stimulus was
equivalent to those induced by the ﬁrst 16.7mM glucose
or mitiglinide stimulations (Figure 1(d), 83.0 ± 7.9, 77.7
± 6.4 and 91.3 ± 13.3/200μm2 for 16.7mM glucose,
mitiglinide and glimepiride, resp.) indicating that the ﬁrst
glimepiride stimulation aﬀected the ability of the response
to the subsequent glimepiride stimulus even after a 15-
minute restoration period, whereas 16.7mM glucose and
mitiglinide could repeatedly evoke the exocytosis of insulin
granules. In order to rule out the possibility that the excess
of glimepiride caused the failure of the exocytotic response
to the second stimulation, we examined the eﬀect of a lower
concentrationonrepetitivestimulation.Primarystimulation
with 0.1μM glimepiride induced about half the number of
fusion events in 12.5 minutes (48.7 ± 6.2/200μm2), but
secondary stimulation with 0.1μM glimepiride failed to
evoke a signiﬁcant exocytotic response (14.9 ± 2.3/200μm2).
To elucidate the mechanism underlying the glimepiride-
induced unresponsiveness to the second stimulation, we
examined the [Ca2+]i dynamics during repetitive stimula-
tions. As shown in Figure 2, the increased [Ca2+]i elicited
by the ﬁrst 16.7 mM glucose returned to the basal level
during a 15-minute interval, and the second high glucose
stimulation again evoked an increase in [Ca2+]i. Mitiglinide
induced a more rapid response than high glucose. The
increased [Ca2+]i steeply decreased to the basal level and
the second mitiglinide stimulation quickly evoked a [Ca2+]i
increase. On the other hand, the elevated [Ca2+]i induced
by the ﬁrst glimepiride stimulation did not return to the
basal level during a 15-minute interval, and the second
glimepiride stimulation failed to cause a further increase in
[Ca2+]i. Continuous washing for more than 30 minutes also
failed to reduce the [Ca2+]i evoked by the ﬁrst glimepiride
stimulation (data not shown). These results suggest that
the ﬁrst glimepiride stimulation elicited a high [Ca2+]i state
for an abnormally long time even after the withdrawal of
glimepiride, resulting in the failure of insulin release in
response to subsequent stimulations.
It is of note that the second glimepiride stimulation
failed to induce the exocytotic response even though [Ca2+]i
during the second stimulus was equivalent to that induced
by the ﬁrst glimepiride stimulation. Thus, we assumed
that the abnormally sustained [Ca2+]i elevation induced by
glimepiride would aﬀect the exocytotic process that is prob-
ably involved in the regulation of insulin granule motility,
because the exocytotic responses evoked by glimepiride were
largely composed of newcomer granules which must move
a long distance from the cytosol to the plasma membrane.
To this end, we investigated the numbers of docked insulin
granules on the plasma membrane after a 15-minute interval
following the ﬁrst stimulation because the motility of insulin
granules should be reﬂected by the number of docked
insulin granules after the onset of stimulation [6]. As shown
in Figure 3, the ﬁrst high glucose and mitiglinide stimuli
did not aﬀect the numbers of docked insulin granules onExperimental Diabetes Research 3
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Figure 1: Histogram of the numbers of fusion events (/200μm2) at 1-minute intervals after stimulation. Cells were perifused with 16.7mM
glucose (N = 16) (a), 0.5μM mitiglinide (N = 17) (b), and 0.5μM glimepiride (N = 11) (c) for 12.5 minutes. After the ﬁrst stimulation, cells
were perifused with 4mM glucose for 15 minutes and stimulated again by the same secretagogues as in the ﬁrst stimulation. Left and right
columns show exocytotic responses during theﬁrst and second stimulations, respectively. (d) The numbers of total fusion events during the
ﬁrst and second stimuli. Data are represented as mean ± S.E.M per 200μm2.
the plasma membrane. On the other hand, the number of
docked insulin granules was decreased to 58.0 ± 4.5% by the
ﬁrst glimepiride stimulation despite the 15-minute recovery
period, suggesting that glimepiride, but not mitiglinide,
would impair the intracellular motility of insulin granules
andtheirrecruitmenttotheplasmamembrane.Theseresults
suggest that the abnormally sustained [Ca2+]i elevation by
primary glimepiride stimulation impaired insulin granule
motility, which might be the cause of the unresponsiveness
to the second glimepiride stimulation.
4. Discussion
In the present study, we examined the eﬀects of SU and glin-
ide drugs on the reversibility of insulin-secreting response
and showed that primary stimulation with SU impaired the
exocytotic response to subsequent stimulation, while glucose
and glinide had the ability to repeatedly induce insulin
release.
Previous pharmacological studies showed that the IC50
values of glimepiride and mitiglinide to exogenously
expressed Kir6.2 and SUR1 were 3.0nM and about 60nM,
respectively [7]. However, in this study, we used mitiglinide
and glimepiride at the same concentration (0.5μM) because
of the following two reasons. First, our previous study
showed that the maximal insulinotropic eﬀect of mitiglinide
was observed at > 0.5μM under TIRF microscopy, indicating
that 0.5μM mitiglinide induced a moderate exocytotic
responseinprimaryculturedβ-cells[8].Second,thenumber
of total fusion events evoked by the ﬁrst 0.5μM glimepiride
stimulation was comparable to that evoked by the ﬁrst
0.5μM mitiglinide stimulation (Figure 1(d)) suggesting that
the maximum insulin-secreting response should not be
induced by 0.5μM glimepiride. Therefore, in our exper-
imental condition, the insulinotropic potencies of 0.5μM
mitiglinide and 0.5μM glimepiride were equivalent. The
validity of the dosages of mitiglinide and glimepiride used
in this study was also proven by the pattern of fusion events
in response to the ﬁrst stimulation. The ﬁrst glimepiride
stimulation evoked fusion events with the highest peak at 7-
8 minutes after the onset of stimulation, whereas the ﬁrst
mitiglinide stimulation induced a more rapid response.
These results were consistent with previous studies showing
that glinide drugs induce a more rapid response than SU
[3]. Furthermore, we conﬁrmed that the ﬁrst stimulation
with glimepiride at a lower concentration induced about half
the number of total fusion events but impaired the insulin-
secreting response to the second stimulation. Taken together,
the diﬀerent exocytotic responses evoked by glimepiride
and mitiglinide were attributed not to the diﬀerence in the
eﬀective concentration but in the character of these drugs.
It is important to elucidate the mechanism underlying
the glimepiride-induced unresponsiveness to subsequent
stimulation. We and others showed that glimepiride induced
an elevation of [Ca2+]i that did not return to the basal level
even after the withdrawal of glimepiride (Figure 2(c)) sug-
gesting that an abnormally sustained [Ca2+]i elevation might
be the cause of the unresponsiveness to subsequent stimula-
tion. It was reported that the abnormally sustained [Ca2+]i
elevation induced by Ca2+ ionophore attenuates the mobility
of secretory granules via disruption of the cytoskeleton in
astrocyte [9]. Several studies have demonstrated that [Ca2+]i
elevation activates multiple pathways for the disruption of
thecytoskeleton,whichmayleadtoattenuationoftheinsulin
granule mobility. Calcium activates Ca2+-dependent pro-
tease, calpain, which cleaves microtubule-associated proteins
(MAPs),resultingindestabilizationofmicrotubuleﬁlaments
[10]. In addition, an increase in [Ca2+]i stimulates Ca2+-
dependent phosphatase, calcineurin, followed by coﬁlin
dephosphorylation via slingshot-mediated pathway, which
leads to depolymerization of actin ﬁlaments [11]. Thus, we
suppose that primary stimulation with glimepiride might
attenuate the insulin granule mobility via disruption of the
cytoskeleton.
In the present study, dispersed primary cultured β-
cells were repeatedly stimulated by perifusion with 16.7mM
glucose. Although the proportion of fusion events from
pre-docked granules was mildly reduced compared to our
previous studies [6], this was due to the diﬀerent stimulation
protocols with a relatively milder stimulation than in our
previous studies [2, 6, 8]. Because fusions from pre-docked
granules require rapid and marked elevation in [Ca2+]PMExperimental Diabetes Research 5
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Figure 2: [Ca2+]i responses to repetitive stimulations. Cells were
perifused with 4mM glucose and then stimulated with 16.7mM
glucose (a), 0.5μM mitiglinide (b), or 0.5μM glimepiride (c) for
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secretagogues as in the ﬁrst stimulation. Data are represented as a
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7 for 16.7mM glucose, mitiglinide, and glimepiride, resp.).
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Figure 3: The numbers of docked insulin granules just before
the second stimulation. Results are mean ± S.E.M percentage
of the numbers of docked insulin granules just before the ﬁrst
stimulation (N = 12, 9, and 10 for 16.7mM glucose, mitiglinide,
and glimepiride, resp.).
[12], perifusion with 16.7mM glucose might not evoke the
steep elevation of [Ca2+]PM required for fusions from pre-
docked granules.
Several decades ago, it was reported that a ﬁrst pulse of
glucose enhanced insulin secretion in response to a second
stimulation.Theprimingeﬀectofglucoseisknownas“time-
dependent potentiation (TDP)” and is observed in isolated
pancreas [13, 14] and islets [15, 16]. In this study, the
ﬁrst and second 16.7mM glucose induced qualitatively the
same exocytotic pattern, but the total number of fusion
events induced by the second 16.7mM glucose was slightly
decreased rather than potentiated. This discrepancy might
be due to the diﬀerent preparation for insulin release assay
because, to our knowledge, there is no report showing
TDP in dispersed β-cells. In this study, we used dispersed
pancreatic β-cells cultured for 2 days in vitro. Thus, cell-cell
interaction or communication in pancreatic islets might be
important for the establishment of TDP. In line with this
speculation, some reports showed the importance of factors
derived from non-β-cells in the formation of “glucose-
memory” [16, 17].
In conclusion, mitiglinide is more beneﬁcial than SU
not only in improving insulin exocytosis but also in the
precise management of [Ca2+]i, which would be important
for maintenance of the insulin-secreting mechanisms in β-
cells.
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